Abstract
Objective: The aim of this study was to determine the frequency of major adverse cardiac events in patients with de novo coronary artery disease revascularized with everolimus-eluting stents.
Methodology: This prospective cross sectional study was carried out in the department of cardiology, Lady Reading Hospital Peshawar from October 2011 to November 2012. Patients with de novo coronary artery disease, who were revascularized with everolimus-eluting stents, were included in the study. Their baseline clinical and procedural characteristics were recorded from hospital record. Data regarding MACE defined as composite of myocardial infarction, stent thrombosis, recurrence of ischemia and death were obtained on follow up.
Results: A total of 420 patients were included in the study in which 320(76.2%) were male. Risk factors for coronary artery disease were; diabetes mellitus 147(35%), hypertension 256(61%), hypercholesterolemia 147(35%) and smoking 100(23.8%). Most of patients had stable angina 285(67.9%). On coronary angiography, 98(23.3%) of patients had single vessel disease, 152(36.2%) had two vessel disease and 170(40.5%) had three vessel disease. Left anterior descending artery was mostfrequently affected vessel 242(57.6%). Mean lesion length was 25 8.1 mm. Mean stent length/lesion was 26.03 7.09 mm while mean stent diameter/lesion was 3.14 0.29mm. Tirofiben (Agrastate) was used in 19(4.5%) of patients. On follow up. MACE occurred in 16(3.8%) patients, 6(1.4%) patients developed myocardial infarction, 5(1.2%) developed recurrence of ischemia, 6(1.4%) of patients developed stent thrombosis and 6(1.4%) of patients died during study period.
Conclusion: Everolimus-eluting stents carries a lower risk of major adverse cardiac events in patients with de novo coronary disease.